Summit Trail Advisors LLC Has $1.46 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Summit Trail Advisors LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,390 shares of the biopharmaceutical company’s stock after purchasing an additional 133 shares during the period. Summit Trail Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,461,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Sachetta LLC boosted its holdings in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares in the last quarter. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares in the last quarter. Stephens Consulting LLC bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at $26,000. Lynx Investment Advisory bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at $33,000. Finally, Family Firm Inc. acquired a new position in Regeneron Pharmaceuticals during the second quarter worth $33,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

REGN opened at $738.00 on Monday. The company has a fifty day moving average price of $945.07 and a two-hundred day moving average price of $1,027.53. The firm has a market capitalization of $81.10 billion, a PE ratio of 18.26, a P/E/G ratio of 2.84 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52 week low of $735.95 and a 52 week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Analyst Ratings Changes

REGN has been the topic of several recent analyst reports. BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Royal Bank of Canada reduced their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Morgan Stanley reduced their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, JPMorgan Chase & Co. decreased their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $1,099.55.

Insider Buying and Selling

In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 7.48% of the stock is owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.